IGF1 deficiency in newly diagnosed Graves' disease patients

Martin, Sorina; Betivoiu, Minodora; Florea, Suzana; Fica, Simona

doi:10.1530/endoabs.37.ep652

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study of patients with new onset Graves' disease, 18.4% had IGF-1 deficiency as defined by serum levels less than 2 standard deviations below normal values for age. 161 No study has been performed linking IGF-1 levels and hearing loss in GD patients. It is unclear whether topical application of IGF-1 would help prevent hearing-related complications secondary to teprotumumab therapy.…”

Section: Infectionsmentioning

confidence: 99%

Teprotumumab

Winn

Kersten

2021

Ophthalmology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Infectionsmentioning

confidence: 99%

Teprotumumab

Winn

Kersten

2021

Ophthalmology

View full text Add to dashboard Cite

show abstract

“…12,13 However, there is also evidence to suggest that IGF1 administration can stimulate regulatory T cells to dampen the immune response. 14–20…”

Section: Introductionmentioning

confidence: 99%

“…12,13 However, there is also evidence to suggest that IGF1 administration can stimulate regulatory T cells to dampen the immune response. [14][15][16][17][18][19][20] Systemic lupus erythematosus (SLE) is the prototypic autoimmune disease, characterised by abnormalities in T-cell and B-cell functionality and a diverse clinical presentation that can lead to organ failure and premature mortality due to an excess of cardiovascular events. 19,21 GH therapy has been used by SLE patients to increase IGF1 levels in spite of the lack of evidence for a possible role of the GH/IGF1 pathway in the pathogenesis of SLE.…”

Section: Introductionmentioning

confidence: 99%

Insulin-like growth factor-1 (IGF1) in systemic lupus erythematosus: relation to disease activity, organ damage and immunological findings

Waldron

Raymond

Ostli-Eilertsen

et al. 2018

Lupus

View full text Add to dashboard Cite

Background Insulin growth factor-1 (IGF1) activates cell proliferation pathways and inhibits apoptosis. IGF1 is involved in tumour growth and required for T-cell independent activation of B cells. Activated B cells and autoantibody production are a hallmark of systemic lupus erythematosus (SLE). To investigate the possible role of IGF1 in SLE, we studied IGF1 across clinical characteristics, immunological biomarkers, disease activity and organ damage in SLE patients. Method In a cross-sectional study, we collected clinical characteristics, medication, disease activity (SLEDAI-2K) and organ damage (SDI) for 94 SLE patients. Autoantibodies and cytokines were measured by ELISA, and levels of IGF1 and IGF binding protein 3 (IGFBP3) by chemiluminescence. Free IGF1 was estimated by the IGF1:IGFBP3 ratio. Healthy controls served as a comparator group. Results There was a significant age-related decline in IGF1, IGFBP3 and free IGF1 (IGF1:IGFBP3 ratio) that was similar in SLE patients and controls with very few outliers. Free IGF1 was inversely related to blood pressure (Rs -0.327, p < 0.01) and HbA1c (Rs -0.31, p < 0.01). Free IGF1 was higher in disease-modifying antirheumatic drug-treated patients ( p < 0.01), but there was no significant association between the IGF1 axis and autoantibody profiles, cytokine levels or SLEDAI-2K or SDI categories. IGF1 correlated inversely with BAFF level and B, natural killer and CD8 + cell counts. Conclusion Free IGF1 levels in SLE patients declined appropriately with age. IGF1 levels were not associated with disease activity, severity or autoantibody levels in SLE. Free IGF1 had positive metabolic effects in SLE and may play an indirect role in dampening the cellular immune response by downregulating B- and T-cell activity.

show abstract

“…Furthermore, complexes containing thyrotropin, IGF-1R and INSR have been detected in orbital fibroblasts and thyroid epithelial cells, the IGF axis is required to maintain thyrotropin signaling, and anti-IGF-1R autoantibodies that activate IGF-1R are detectable in patients with GD [87,90,91]. Thus, although cross-talk between thyrotropin and IGF signaling has been recognized for over 30 years, it is only recently that IGF-1R activation has been implicated in driving the immunopathogenesis of GD [87,88,92,93].…”

Section: Thyroid Eye Diseasementioning

confidence: 99%

Faculty Opinions recommendation of Therapeutic targeting of the IGF axis.

Kurokawa

Nakase

2020

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

View full text Add to dashboard Cite

The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging.

show abstract

IGF1 deficiency in newly diagnosed Graves' disease patients

Cited by 3 publications

References 0 publications

Teprotumumab

Teprotumumab

Insulin-like growth factor-1 (IGF1) in systemic lupus erythematosus: relation to disease activity, organ damage and immunological findings

Faculty Opinions recommendation of Therapeutic targeting of the IGF axis.

Contact Info

Product

Resources

About